DOCSLIB.ORG

Gemfibrozil in the Treatment of Dyslipidemia an 18-Year Mortality Follow-Up of the Helsinki Heart Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gemfibrozil in the Treatment of Dyslipidemia an 18-Year Mortality Follow-Up of the Helsinki Heart Study ORIGINAL INVESTIGATION Gemfibrozil in the Treatment of Dyslipidemia An 18-Year Mortality Follow-up of the Helsinki Heart Study Leena Tenkanen, PhD; Matti Ma¨ntta¨ri, MD; Petri T. Kovanen, MD; Hanna Virkkunen, MSc; Vesa Manninen, MD Background: The Helsinki Heart Study was a double- Cox proportional hazards models with and without blind, placebo-controlled primary prevention trial among covariates. 4081 dyslipidemic middle-aged men to test the efficacy of gemfibrozil in the prevention of coronary heart dis- Results: During the follow-up until 1995, subjects in the ease (CHD). After the 5-year trial, the participants were OG group had a 32% lower RR of CHD mortality (P=.03) notified of their treatment group and invited to con- compared with those in the OP group, and when followed tinue or start gemfibrozil therapy free of charge through up until 2000, the RR was 23% lower (P=.05). Overall, there 1995. Approximately two thirds of participants in both were no differences in all-cause or cancer mortality. How- groups chose gemfibrozil therapy. In this 18-year fol- ever, those in the OG group with both body mass index low-up through 2000, we compared the CHD, cancer, and triglyceride level in the highest tertiles had a 71% lower Ͻ and all-cause mortality among subjects in the original gem- RR of CHD mortality (P .001), a 33% lower RR of all- fibrozil (OG) group (n=2046) with those in the origi- cause mortality (P=.03), and a 36% lower RR of cancer mor- nal placebo (OP) group (n=2035). tality (P=.22) compared with those in the OP group. Conclusion: Long-term mortality follow-up showed that Methods: To provide an overview of the absolute risks patients with dyslipidemia benefited from beginning treat- in the 2 treatment groups as well as risk differences ment with gemfibrozil early, especially if their dyslipid- between them, we calculated crude mortality rates and emia entailed factors related to the metabolic syndrome. presented Kaplan-Meier plots of survival with log-rank tests. We also estimated the relative risks (RRs) using Arch Intern Med. 2006;166:743-748 HE HELSINKI HEART STUDY from the treatment was characterized by was a 5-year primary pre- a high baseline triglyceride (TG) level vention trial to test the hy- and an elevated ratio of LDL-C to pothesis that gemfibrozil HDL-C.5 Further analyses indicated that use reduces coronary heart gemfibrozil use reduced CHD risk espe- Tdisease (CHD) incidence by lowering low- cially in overweight subjects with addi- density lipoprotein cholesterol (LDL-C) tional risk factors known to contribute and increasing high-density lipoprotein or predispose to the metabolic syn- cholesterol (HDL-C) levels. During the drome.6 The effect of gemfibrozil therapy Author Affiliations: Helsinki original 5-year, double-blind phase of the in subjects with insulin resistance was Heart Study, Helsinki, Finland trial, a 34% reduction in cardiac end points, later confirmed in the Veterans Affairs (Drs Tenkanen, Mänttäri, and but no difference in all-cause mortal- High Density Lipoprotein Intervention Manninen and Ms Virkkunen); 1,2 7 School of Public Health, ity, was seen. When the 5-year trial Trial (VA-HIT). Tampere University, Tampere, ended, the participants in both treatment Finland (Dr Tenkanen and groups were offered gemfibrozil for the fol- Ms Virkkunen); Helsinki lowing 3.5 years. At the end of the 3.5- See also pages 715 and 737 University Jorvi Hospital, year open-label phase, the effect of long- Espoo, Finland (Dr Ma¨ntta¨ri); term vs short-term treatment with The present study is an 18-year fol- Helsinki University Central gemfibrozil was studied. No material dif- low-up of the original gemfibrozil (OG) and Hospital, Helsinki ferences in all-cause or coronary mortal- original placebo (OP) groups of the Hel- (Dr Manninen); and Wihuri ity were seen between the original treat- sinki Heart Study to examine the effects of Research Institute, Helsinki ment groups,3 whereas cancer mortality a 5-year earlier start of gemfibrozil treat- (Drs Ma¨ntta¨ri and Kovanen). was slightly (nonsignificantly) higher in ment on all-cause, CHD, and cancer mor- Group Information: 4 Drs Tenkanen, Mänttäri, and the original gemfibrozil group. tality. We also investigated whether the Manninen and Ms Virkkunen Subsequent subgroup analyses of the findings from the subgroup analyses of are members of the Helsinki double-blind trial data showed that the the double-blind trial phase would persist Heart Study Group. group that obtained the greatest benefit in the long-term analysis of mortality. (REPRINTED) ARCH INTERN MED/ VOL 166, APR 10, 2006 WWW.ARCHINTERNMED.COM 743 ©2006 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 Free Gemfibrozil A OG Group Group Double Blind Open Label Treatment 2.20 OP Group Placebo Gemfibrozil (n = 1320) OP 2.00 (n = 2035) No Drug (n = 608) 1.80 1.60 Gemfibrozil Gemfibrozil (n = 1301) OG 1.40 (n = 2046) No Drug (n = 660) 1.20 TG Level, mmol/L 8.5-y Follow-up 1.00 13-y Follow-up 18-y Follow-up B Clinical Follow-up 1.40 Register-Based Follow-up 1.35 1.30 1981-1982 1986-1987 1990 1995 2000 1.25 Calendar Year 1.20 HDL-C Level, mmol/L 1.15 Figure 1. Schematic presentation of the different phases of the 18-year follow-up of the Helsinki Heart Study. OG indicates original gemfibrozil; OP, original placebo. C 5.20 METHODS 5.00 4.80 DIFFERENT PHASES 4.60 OF THE HELSINKI HEART STUDY 4.40 LDL-C Level, mmol/L 4.20 Double-blind Trial Baseline 1 2 3 4 5 6 7 8 The Helsinki Heart Study was a 5-year, double-blind clinical trial Years to test the hypothesis that lowering serum LDL-C and triglyc- Double Blind Open Label eride levels and elevating serum HDL-C levels with gemfibrozil 1981-1982 1986-1987 1990 reduces CHD risk in middle-aged dyslipidemic men. The de- Calendar Year sign, conduct, and main results of the study have been de- 1,2 scribed in detail. Briefly, the volunteers for the trial were se- Figure 2. Development of annual mean values of triglyceride (TG) (A), lected in 1980 through 1982 by 2 successive screenings from men high-density lipoprotein cholesterol (HDL-C) (B), and low-density lipoprotein aged 40 to 55 years, employed by 2 government agencies and 5 cholesterol (LDL-C) (C) in the original placebo (OP) and original gemfibrozil industrial companies. To be eligible for the second screening or (OG) groups during the double-blind and open-label trials. To convert to for the trial, the subjects’ non–HDL-C level had to be 200 mg/dL milligrams per deciliter, divide by 0.0113 for TG and by 0.0259 for HDL-C and LDL-C. (5.2 mmol/L) or higher, and for the trial they also had to be with- out evidence of CHD or any other major illness. Of 18 936 men tality by linkage to population-based registers, especially the at the first screening, 4081 met these criteria and were willing Cause-of-Death Register kept by Statistics Finland, Helsinki. In to participate in the trial. Of these, 2035 were randomized to re- Finland, there is a centralized nationwide population registra- ceive placebo and 2046 to receive gemfibrozil, 1200 mg/d, 2 cap- tion system based on personal identification numbers, kept since sules twice daily. Compliance with medication was studied by 1966. This system ensures that the registration of deaths is vir- 8 several methods (eg, capsule counting). tually complete. The Cause-of-Death Register was found to be very reliable in terms of CHD deaths compared with the World Open-Label Phase Health Organization Monitoring of Trends and Determinants in Cardiovascular Disease (WHO MONICA) project data9 and the At the end of the 5-year trial, all subjects (including dropouts) were Helsinki Heart Study data.10 informed about their lipid values during the trial and invited to par- ticipate in an open 3.5-year trial extension with 2 annual visits and Present Mortality Follow-up a choice to take gemfibrozil (Figure 1). About the same propor- tion of subjects in the 2 original treatment groups chose to take This study extends the follow-up from the beginning of the double- gemfibrozil: 66.3% in the OG group and 68.5% in the OP group. blind trial in 1980-1982 through 2000 (18-year follow-up) and Compliance monitoring showed that in both groups the partici- is fully register based. The following CHD codes were moni- 3 pant took, on average, 3.5 capsules of gemfibrozil per day. tored: International Classification of Diseases, Eighth Revision codes 410 to 414 through 1986; International Classification of Diseases, Register-Based Follow-up Phase Ninth Revision codes 4100 to 4199 from 1987 through 1995; and International Statistical Classification of Diseases, 10th Revision codes At the end of the open-label phase in June 1990, subjects taking I20 to I25 from 1996 through 2000. These codes imply the pres- gemfibrozil were offered a free drug supply through a central phar- ence of 1 or several of the following conditions: angina, myocar- macy through 1995, but no regular follow-up visits. The trial co- dial infarction, myocardial infarction with complications, other hort was then followed up for all-cause, CHD, and cancer mor- ischemic heart diseases, and chronic ischemic heart disease. (REPRINTED) ARCH INTERN MED/ VOL 166, APR 10, 2006 WWW.ARCHINTERNMED.COM 744 ©2006 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 Table 1.
Load more

Recommended publications
  • Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
    Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value Draft Evidence Report November 12, 2020 Prepared for ©Institute for Clinical and Economic Review, 2020 ICER Staff and Consultants Modeling Team Grace A. Lin, MD, MAS Dhruv S. Kazi, MD, MSc, MS Associate Professor of Medicine and Health Policy Associate Director, Smith Center for Outcomes University of California, San Francisco Research in Cardiology Director, Cardiac Critical Care Unit Jane Jih, MD, MPH Beth Israel Deaconess Medical Center Assistant Professor, Division of General Internal Associate Professor, Harvard Medical School Medicine University of California, San Francisco Foluso Agboola, MBBS, MPH Director, Evidence Synthesis Dr. Kazi was responsible for the development of the ICER cost-effectiveness model, interpretation of results, and drafting of the economic sections of this report; the Rick Chapman, PhD, MS resulting ICER reports do not necessarily represent the Director of Health Economics views of Beth Israel Deaconess Medical Center or ICER Harvard Medical School. Steven D. Pearson, MD, MSc President ICER DATE OF PUBLICATION: November 12, 2020 How to cite this document: Lin GA, Kazi DS, Jih J, Agboola F, Chapman R, Pearson SD. Inclisiran and Bempedoic Acid for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value; Draft Evidence Report. Institute for Clinical and Economic Review, November 12, 2020. https://icer-review.org/material/high-cholesterol-update- draft-evidence-report/ Grace Lin served as the lead author for the report and wrote the background, other benefits, and contextual considerations sections of the report, with Jane Jih serving as a co-author.
    [Show full text]
  • PI Changes for Fibrates
    Changes to Product Information as approved by the CHMP on 21 October 2010, pending endorsement by the European Commission 1 BEZAFIBRATE ANNEX I -SUMMARY OF PRODUCT CHARACTERISTICS 4.1 Therapeutic indications (to replace current text) [Product name] is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following: - Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol. - Mixed hyperlipidaemia when a statin is contraindicated or not tolerated. 5.1 Pharmacodynamic properties (Additional text) There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease ANNEX III -LABELLING AND PACKAGE LEAFLET What [Product name] is and what it is used for [Product name] belongs to a group of medicines, commonly known as fibrates. These medicines are used to lower the level of fats (lipids) in the blood. For example the fats known as triglycerides. [Product name] is used, alongside a low fat diet and other non-medical treatments such as exercise and weight loss, to lower levels of fats in the blood. 2 CIPROFIBRATE ANNEX I -SUMMARY OF PRODUCT CHARACTERISTICS 4.1 Therapeutic indications (to replace current text) [Product name] is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following: - Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol. - Mixed hyperlipidaemia when a statin is contraindicated or not tolerated. 5.1 Pharmacodynamic properties (Additional text) There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease ANNEX III -LABELLING AND PACKAGE LEAFLET What [Product name] is and what it is used for [Product name] belongs to a group of medicines, commonly known as fibrates.
    [Show full text]
  • Fenofibrate, Bezafibrate, Ciprofibrate and Gemfibrozil Procedure Number
    28 February 2011 EMA/CHMP/580013/2012 Assessment report for fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil containing medicinal products pursuant to Article 31 of Directive 2001/83/EC, as amended INN: fenofibrate, bezafibrate, ciprofibrate and gemfibrozil Procedure number: EMEA/H/A-1238 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical aspects .................................................................................................... 4 2.2.1. PhVWP recommendation ..................................................................................... 4 2.2.2. CHMP review ..................................................................................................... 7 2.2.3. Discussion .....................................................................................................
    [Show full text]
  • Lipid Lowering Drugs Prescription and the Risk of Peripheral Neuropathy
    1047 J Epidemiol Community Health: first published as 10.1136/jech.2003.013409 on 16 November 2004. Downloaded from RESEARCH REPORT Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases Giovanni Corrao, Antonella Zambon, Lorenza Bertu`, Edoardo Botteri, Olivia Leoni, Paolo Contiero ............................................................................................................................... J Epidemiol Community Health 2004;58:1047–1051. doi: 10.1136/jech.2003.013409 Study objective: Although lipid lowering drugs are effective in preventing morbidity and mortality from cardiovascular events, the extent of their adverse effects is not clear. This study explored the association between prescription of lipid lowering drugs and the risk of peripheral neuropathy. Design: A population based case-control study was carried out by linkage of several automated databases. Setting: Resident population of a northern Italian Province aged 40 years or more. Participants: Cases were patients discharged for peripheral neuropathy in 1998–1999. For each case up See end of article for authors’ affiliations to 20 controls were randomly selected among those eligible. Altogether 2040 case patients and 36 041 ....................... controls were included in the study. Exposure ascertainment: Prescription drug database was used to assess exposure to lipid lowering drugs Correspondence to: Professor G Corrao, at any time in the one year period preceding the index date.
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Front Matter (PDF)
    600-mg Tablets LOPID is indicated for reducing the risk of coronary heart disease in type lib patients with low HDL, in addition to elevated LDL and triglycerides, and who have had an inadequate response to weight loss, diet, exercise, and other pharmacologic agents such as bile acid sequestrants and nicotinic acid. LOPID is not indicated for the treatment of Ratients with low HDL cholesterol as their onlyJiRid abnormality. Reduced heart attack incidence up to 62%* -in Helsinki Heart Study patients whose baseline HDL was < 35 mgldL and median baseline LDL was 186 mgldL.1 Incidence of serious coronary events was similar for LOPID and placebo subgroups with baseline HDL, above the median (46.4 mgldL).1 Raised low HDL 25% -in these Helskinki Heart Study patients.1 RAISES HDL, LOWERS LDL AND TRIGLYCERIDES DRAMATICALLY REDUCES HEART ArrACK Contraindicated in patients with hepatic or severe renal dysfunction, including primary biliary cirrhosis, preexisting gallbladder disease, or hypersensitivity to gemfibrozil. LOPID may increase cholesterol secretion into the bile, leading to cholelithiasis. Caution should be exercised when anticoagulants are given in conjunction with LOPID. 'Defined as a combination of definite coronary death andlor definite myocardial infarction, P - .013; 95% CI 13.3 to 111.5. Reference 1. Data on file. Medical Affairs Dept. Parke.Davi" Please see last page of this advertisement for warnings, contraindications, and brief summary of prescribing information. LopId'" (Gemfibrozil Capsules and Tablets) Lopld"' (Gemfibrozil Capsules and Tablets) Before prnc:riblng, pte __ full prnc:rlblng Infol'lMtlon. from controls in the incidence of liver tumors. but the doses tested were lower than those A BrIef SUmmary followa.
    [Show full text]
  • Therapeutic Class Overview Fibric Acid Derivatives
    Therapeutic Class Overview Fibric Acid Derivatives Therapeutic Class • Overview/Summary: The fibric acid derivatives are agonists of the peroxisome proliferator activated receptor α (PPARα). Activation of PPARα increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein CIII. The resulting decrease in triglycerides (TG) produces an alteration in the size and composition of low- density lipoprotein cholesterol (LDL-C) from small, dense particles to large buoyant particles. There is also an increase in the synthesis of high-density lipoprotein cholesterol (HDL-C), as well as apoprotein AI and AII.1-10 The major action of this class of medications is to reduce TG. The fibric acid derivatives can decrease TG by 20 to 50% and increase HDL-C by 10 to 35%. They also lower LDL- C by 5 to 20%; however, in patients with hypertriglyceridemia, LDL-C may increase with the use of fibric acid derivatives.11 Several fenofibrate products are currently available, including micronized and non-micronized formulations. The different fenofibrate formulations are not equivalent on a milligram-to-milligram basis. Micronized fenofibrate is more readily absorbed than non-micronized formulations, which allows for a lower daily dose. Fenofibrate (micronized and non-micronized formulations), fenofibric acid, and gemfibrozil are available generically in at least one dosage form and/or strength.12 Fenofibrate and fenofibric acid are Food and Drug Administration (FDA)-approved for the treatment of hypercholesterolemia and mixed dyslipidemias, as well as hypertriglyceridemia. Gemfibrozil is FDA- approved for the treatment of hypertriglyceridemia and to reduce the risk of developing coronary heart disease (CHD) in select patients.13 Gemfibrozil has demonstrated a reduction in the risk of fatal and nonfatal myocardial infarction (MI) for primary prevention, as well as a reduction in CHD death and nonfatal MI and stroke for secondary prevention.
    [Show full text]
  • Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
    pharmacy Article Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs Donatella Zodda 1,*, Rosario Giammona 2 and Silvia Schifilliti 2 1 Drug Department of Local Health Unit (ASP), Viale Giostra, 98168 Messina, Italy 2 Clinical Pharmacy Fellowship, University of Messina, Viale Annunziata, 98168 Messina, Italy; [email protected] (R.G.); silvia.schifi[email protected] (S.S.) * Correspondence: [email protected]; Tel.: +39-090-3653902 Received: 12 November 2017; Accepted: 11 January 2018; Published: 21 January 2018 Abstract: Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C). However, due to adherence to statin therapy or statin resistance, many patients do not reach LDL-C target levels. Ezetimibe, fibrates, and nicotinic acid represent the second-choice drugs to be used in combination with statins if lipid targets cannot be reached. In addition, anti-PCSK9 drugs (evolocumab and alirocumab) provide an effective solution for patients with familial hypercholesterolemia (FH) and statin intolerance at very high cardiovascular risk. Recently, studies demonstrated the effects of two novel lipid-lowering agents (lomitapide and mipomersen) for the management of homozygous FH by decreasing LDL-C values and reducing cardiovascular events. However, the costs for these new therapies made the cost–effectiveness debate more complicated. Keywords: lipid lowering therapy; dyslipidemia; statins; fibrate; PCSK9 inhibitors; lomitapide 1.
    [Show full text]
  • A Review of the Efficacy and Tolerability of Bempedoic Acid In
    American Journal of Cardiovascular Drugs https://doi.org/10.1007/s40256-020-00399-w REVIEW ARTICLE A Review of the Efcacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia Stephanie Niman1 · Khyatiben Rana1 · Jessica Reid1,2 · Mae Sheikh‑Ali3 · Todd Lewis4 · Rushab R. Choksi1 · Rebecca F. Goldfaden1 © Springer Nature Switzerland AG 2020 Abstract Despite the widespread use of statins and ezetimibe to decrease low-density lipoprotein cholesterol (LDL-C) levels and associated atherosclerotic cardiovascular disease (ASCVD), many patients do not achieve adequate LDL-C lowering as per the recommended American College of Cardiology (ACC)/American Heart Association (AHA) and European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines and demonstrate residual cardiovascular risk. The introduction of proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors in 2015 was a promising addition to hypercholesterolemia therapies, but their cost and subcutaneous administration has limited their use, and therefore, new afordable and patient friendly treatment strategies are crucial to help reduce ASCVD risk. Bempedoic acid, a drug currently under investigation, is a small molecule that has been shown to upregulate LDL receptors, decrease LDL-C, and reduce atherosclerotic plaque formation in hypercholesterolemic patients. Furthermore, bempedoic acid is a prodrug that becomes activated by an enzyme expressed primarily in the liver, allowing it to avoid the potential myotoxicity associated with statin
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Gemfibrozil Induces Anemia, Leukopenia and Reduces Hematopoietic Stem Cells Via PPAR
    International Journal of Molecular Sciences Article Gemfibrozil Induces Anemia, Leukopenia and Reduces Hematopoietic Stem Cells via PPAR-α in Mice Gabriel Rufino Estrela 1,2,* , Adriano Cleis Arruda 2,3, Heron Fernandes Vieira Torquato 4,5, Leandro Ceotto Freitas-Lima 3 , Mauro Sérgio Perilhão 2,3, Frederick Wasinski 6 , Alexandre Budu 3, Ricardo Ambrósio Fock 7, Edgar Julian Paredes-Gamero 4,8 and Ronaldo Carvalho Araujo 2,3,* 1 Department of Clinical and Experimental Oncology, Discipline of Hematology and Hematotherapy, Federal University of São Paulo, São Paulo 04037002, Brazil 2 Department of Medicine, Discipline of Nephrology, Federal University of São Paulo, São Paulo 04039032, Brazil; [email protected] (A.C.A.); [email protected] (M.S.P.) 3 Department of Biophysics, Federal University of São Paulo, São Paulo 04039032, Brazil; [email protected] (L.C.F.-L.); [email protected] (A.B.) 4 Department of Biochemistry, Federal University of São Paulo, São Paulo 04044020, Brazil; [email protected] (H.F.V.T.); [email protected] (E.J.P.-G.) 5 Faculty of Pharmacy, University Center Braz Cubas, Mogi das Cruzes 08773380, Brazil 6 Department of Physiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508000, Brazil; [email protected] 7 Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508000, Brazil; [email protected] 8 Faculty of Pharmaceutical, Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul 79070900, Brazil * Correspondence: [email protected] (G.R.E.); [email protected] (R.C.A.); Tel.: +55-11-5576-4859 (R.C.A.) Received: 9 June 2020; Accepted: 6 July 2020; Published: 17 July 2020 Abstract: Hypercholesterolemia, also called high cholesterol, is a form of hyperlipidemia, which may be a consequence of diet, obesity or diabetes.
    [Show full text]
  • Antidiabetic Action of Bezafibrate in a Large Observational Database
    Diabetes Care Publish Ahead of Print, published online January 8, 2009 Bezafibrate for Prevention of Diabetes Antidiabetic Action of Bezafibrate in a Large Observational Database James H Flory BA*, Susan Ellenberg PhD*, Philippe O Szapary MD, MSCE*†¥, Brian L Strom MD* MPH, Sean Hennessy PharmD PhD* * Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Blockley Hall, 423 Guardian Drive, Philadelphia, PA, 19103 (all authors) † Centocor Research and Development, Malvern, PA 19355 ¥ Preventive Cardiovascular Medicine and Lipid Clinic, Department of Medicine, University of Pennsylvania Health System, Philadelphia, PA 19104. Correspondence to: James Flory, [email protected] Submitted 2 October and accepted 4 January 2009. This is an uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American Diabetes Association, publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher- authenticated version will be available in a future issue of Diabetes Care in print and online at http://care.diabetesjournals.org. Copyright American Diabetes Association, Inc., 2009 Bezafibrate for Prevention of Diabetes Objective: To test the hypothesis that bezafibrate, an approved fibrate, can prevent or delay type 2 diabetes. Research Design and Methods: Retrospective cohort study using data from routine medical practice in the United Kingdom, as captured by the General Practitioner’s Research Database (GPRD). Individuals chronically exposed to bezafibrate were compared to individuals chronically exposed to other fibrates. Hazard ratios for incident type 2 diabetes mellitus were calculated using a Cox proportional hazards model.
    [Show full text]